Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 380 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Botox Injection Clear all
Completed Not applicable Interventional Results available

Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain

NCT02369068
View directory record Official record
Conditions
Pelvic Pain
Interventions
Onabotulinumtoxin A, Kenalog
Drug
Lead sponsor
Jamie Bartley, DO
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 19, 2026, 3:29 AM EDT
Recruiting Phase 3 Interventional

Injection of Botulinum Toxin for Thumb Carpometacarpal Arthritis

NCT05990881
View directory record Official record
Conditions
Carpometacarpal Sprain, Thumb Sprain, Clostridium; Botulinum
Interventions
Botulinum toxin, Standard-of-care corticosteroid injections
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 19, 2026, 3:29 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer

NCT07796490
View directory record Official record
Conditions
Prostate Cancer
Interventions
OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo
Drug · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 19, 2026, 3:29 AM EDT
Recruiting Phase 2 Interventional

Zinc as an Adjunctive Therapy for Cervical Dystonia

NCT07140874
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Zinc citrate, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 19, 2026, 3:29 AM EDT
Terminated Not applicable Interventional Results available

TENS Used for Pain Management During Office Cystoscopy Botox Injections

NCT04448171
View directory record Official record
Conditions
Overactive Bladder
Interventions
Active TENS, Sham TENS
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 19, 2026, 3:29 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

NCT00770211
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Englewood, Colorado • Aventura, Florida • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 19, 2026, 3:29 AM EDT
Withdrawn Phase 2 Interventional

Botulinum Toxin for Carpal Tunnel Syndrome

NCT00701233
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Botulinum toxin, Corticosteroid injection into Carpal Tunnel
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 19, 2026, 3:29 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia

NCT04849988
View directory record Official record
Conditions
Cervical Dystonia
Interventions
ABP-450, Placebo
Drug
Lead sponsor
AEON Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 19, 2026, 3:29 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00439140
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 19, 2026, 3:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

NCT04247074
View directory record Official record
Conditions
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Interventions
botulinum toxin neuromodulator, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
11
States / cities
Encino, California • Santa Monica, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 19, 2026, 3:29 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

NCT07122193
View directory record Official record
Conditions
Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents, incobotulinumtoxinA, Botulinum Toxins, Type A
Interventions
NT 201, NT 201 Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 19, 2026, 3:29 AM EDT
Withdrawn Phase 2 Interventional

Botulinum Toxin Injection for Functional Popliteal Artery Entrapment Syndrome

NCT03631966
View directory record Official record
Conditions
Functional Popliteal Artery Entrapment Syndrome, Popliteal Artery Entrapment Syndrome
Interventions
Dysport
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 19, 2026, 3:29 AM EDT
Recruiting Phase 4 Interventional

Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection

NCT06953271
View directory record Official record
Conditions
Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis)
Interventions
Methenamine Hippurate, Typically prescribed oral antibiotic prophylaxis
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 19, 2026, 3:29 AM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 19, 2026, 3:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A

NCT05466539
View directory record Official record
Conditions
Compartment Syndrome of Leg
Interventions
AbobotulinumtoxinA, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Brookhaven, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 19, 2026, 3:29 AM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Lower Limb Spasticity Follow-on Study

NCT01251367
View directory record Official record
Conditions
Post-stroke Spasticity, Spasticity Post-Traumatic Brain Injury
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Scottsdale, Arizona • Downey, California • Oxnard, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 19, 2026, 3:29 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection

NCT04817865
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST), Urine Culture
Diagnostic Test
Lead sponsor
Pathnostics
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Barrington, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 19, 2026, 3:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

DaxibotulinimtoxinA for Treatment of Platysmal Neck Bands

NCT06225492
View directory record Official record
Conditions
Aging
Interventions
DaxibotulinumtoxinA 15 units, DaxibotulinumtoxinA 20 units
Drug
Lead sponsor
Main Line Center for Laser Surgery
Other
Eligibility
31 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 19, 2026, 3:29 AM EDT
Completed Phase 2 Interventional Results available

Dysport in Hallux Abducto Valgus (HAV) Phase IIa

NCT03569098
View directory record Official record
Conditions
Hallux Abducto Valgus
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Castro Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 19, 2026, 3:29 AM EDT
Completed Phase 4 Interventional

Botox or Botox With Esophageal Dilation in Patients With Achalasia

NCT03654066
View directory record Official record
Conditions
Achalasia
Interventions
Botulinum toxin type A, Endoscope balloon dilator, Patient reported outcomes, Barium esophagram
Drug · Device · Other + 1 more
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 3:29 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization

NCT05478551
View directory record Official record
Conditions
Scar, Hypertrophic Scar
Interventions
Botulinum Toxin, Normal saline
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 19, 2026, 3:29 AM EDT
Not listed Not applicable Interventional

Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain

NCT01905137
View directory record Official record
Conditions
Myofascial Pelvic Pain
Interventions
Intervention-Botulinum Toxin Type A, placebo
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 19, 2026, 3:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Novel Technique for Botulinum Toxin Injection to Minimize Patient Discomfort

NCT00628472
View directory record Official record
Conditions
Pain
Interventions
botulinum type a
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 19, 2026, 3:29 AM EDT
Terminated Phase 4 Interventional Results available

Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint

NCT01045694
View directory record Official record
Conditions
Arthritis Multiple Joint
Interventions
Botulinum Toxin Type A, Steroid - Triamcinolone Acetonide, Lidocaine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 19, 2026, 3:29 AM EDT